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Veronesi, Galetta, Leo, Borri (left to right)Superior vena cava (SVC) resection for lung cancer istechnically feasible, with encouraging oncologic resultswhen modern selection criteria are used.1 However,some questions still remain, mainly those regarding
which type of prosthetic replacement to use after complete SVC
substitution. We successfully experimented with a new revascu-
larization technique for SVC replacement after its complete resec-
tion for lung cancer, using a heterologous (bovine) custom-made
pericardial prosthesis, and we report the early outcome (oncologic
and graft patency results) of a preliminary consecutive series.
Clinical Summary
From 1998, 70 patients underwent SVC system resection for lung
and mediastinal malignancies: 34 (49%) received prosthetic re-
placement, and of these, the last 5 patients underwent SVC revas-
cularization with a heterologous (bovine) custom-made pericardial
prosthesis.
The surgical approach used was either a large muscle–sparing
lateral thoracotomy in the anterior fourth rib section (n  4) or a
right hemiclamshell approach (n  1). After radical lymph node
dissection and before lung resection, the SVC was completely
removed, and vascular continuity was restored by using the bio-
logical prosthesis. A heterologous bovine pericardial patch (No
React pericardial patch; Shelhigh, Millburn, NJ; original size, 10 
20 cm) was used (Figure 1, A); it was made tubular with a running
5-0 polypropylene suture (Figure 1, B).
The length of the biological tube used depended on the degree
of SVC involvement and was thus variable. The diameter, con-
versely, was quite standard—approximately 20 mm after the patch
was wrapped around a syringe (Figure 1, B).
The anastomosis between the heterologous biological prosthe-
sis and the SVC was performed with 5-0 polypropylene sutures
(Figure 2). All resections were performed with the crossclamping
From the Departments of Thoracic Surgery,a Pathology,b and Anesthesi-
ology,c European Institute of Oncology, Milan, Italy.
Received for publication Aug 23, 2005; revisions accepted Aug 26, 2005;
accepted for publication Sept 9, 2005.
Address for reprints: Lorenzo Spaggiari, MD, PhD, Department of Thoracic
Surgery, European Institute of Oncology, via Ripamonti 435, 20141 Milan,
Italy (E-mail: lorenzo.spaggiari@ieo.it).
J Thorac Cardiovasc Surg 2006;131:491-2
0022-5223/$32.00
Copyright © 2006 by The American Association for Thoracic Surgery
doi:10.1016/j.jtcvs.2005.09.011
490 The Journal of Thoracic and Cardiovascular Surgery ● Febrtechnique.2 Low doses of low-weight heparin were administered
after surgery up until 1 month after discharge. All patients were
followed up by using a computed tomographic thoracic scan every
3 months.
From October 2003, 5 other consecutive patients underwent
operation. All but 1 underwent induction chemotherapy after me-
diastinoscopy. The mean SVC system clamping time was 31
minutes. Lung resection was performed with a tracheal sleeve
pneumonectomy in 4 cases and a right upper lobectomy in the
remaining case. One patient died during the postoperative period
as a result of pneumonia. The others had uneventful postoperative
outcomes, with a mean postoperative hospital stay of 8 days.
During follow-up, 1 patient died at 3 months as a result of
evolving disease. Three patients are still alive and disease free (at
21, 8, and 8 months) without signs (on computed tomographic
thoracic scan) of late graft thrombosis.
Discussion
Normally, an autologous pericardial patch is used in cardiac sur-
gery, in reconstruction of the pulmonary artery, and sometimes in
the closing of partial vascular defects after SVC or pulmonary
artery surgery for lung and mediastinal malignancies.1,3 An autol-
ogous pericardium is ideal in these situations because of the lower
risk of infection and thrombosis compared with a synthetic pros-
thesis; besides, it does not require anticoagulation therapy. How-
ever, an autologous pericardium is not sufficient for creating a long
tube after complete SVC resection. In fact, in these situations, SVC
replacement with a synthetic (polytetrafluoroethylene) prosthesis
is mandatory. The problem with using synthetic prostheses is
manifold: the need for prolonged full anticoagulation therapy, the
risk of infection (mainly after lung resection), and early graft
thrombosis. Plus, little is known about the long-term patency of the
synthetic graft after great venous vessel replacement. On the basis
of our previous experience with SVC surgery for lung cancer,1,2,4
we decided to use biological material instead of a polytetrafluo-
roethylene graft because of the various risks involved in using a
synthetic graft. We choose the bovine pericardial patch because it
was experimentally studied in animal models,5 which showed long
patency of the graft; however, up to now, no human experience
concerning SVC replacement with pericardial bovine tube has
been reported. Modern biocompatible pericardial patches were
introduced recently into c
uary 2006linical cardiothoracic surgical practice.
Brief CommunicationsThis patch shows an increased thickness with respect to the human
one, it does not shrink, and it retains suture better than fresh
pericardium. These patches are totally detoxified, reaching full
biocompatibility. These characteristics probably should influence
graft patency; in fact, our first patient, still alive and disease free,
presented a patent graft at the last follow-up at 21 months after
surgery. The other 2 patients, still alive and disease free, have
patent grafts at 8 months.
This preliminary experience with 5 consecutive patients con-
firms that a long tube can be constructed by using a bovine
pericardial patch. Current heterologous pericardial tubes are able
to retain all the advantages of autologous ones, with no size limits
and with excellent results in terms of graft patency.
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Figure 1. A, Bovine pericardial patch is prepared
according to the length of superior vena cava re-
section. B, Heterologous bovine pericardial patch is
made tubular by a running 5-0 polypropylene suture.
Figure 2. A, Operative picture during superior vena
cava (SVC) reconstruction: the proximal anastomo-
sis is in progress. B, SVC replacement with the
heterologous pericardial tube is complete.Can J Surg. 1992;35:305-9.
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